Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating medicines treating hormone-responsive cancers. It develops Onapristone ER (extended release), an investigational drug for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. Additionally, the company provides CTX-030916, an oral antiprogestin for the treatment of uterine fibroids and endometriosis.